The Potential Role of Renal Denervation in the Management of Heart Failure
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Sympathetic nervous system activation in patients with heart failure is one of the main pathophysiologic mechanisms associated with the worse outcomes. Pharmacotherapies targeting neurohormonal activation have been at the center of heart failure management. Despite the advancement of therapies and the available treatments, heart failure continues to have an overall poor prognosis. Renal denervation was originally developed to lower systemic blood pressure in patients with poorly controlled hypertension, by modulating sympathetic outflow. However, more recently, multiple studies have investigated the effect of renal denervation in heart failure patients with both preserved (HFpEF) and reduced ejection fractions (HFrEF). This paper provides an overview of the potential effect of renal denervation in altering the various pathophysiologic, sympathetically mediated pathways that contribute to heart failure, and reviews the literature that supports its future use in those patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, RDN-induced reductions in MSNA18 and beneficial effects of RDN on conditions that are not traditionally thought to be driven by the kidney, including heart failure and arrthymia19, cannot be wholly explained by alterations in body fluid homeostasis.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 1×
“Large scale clinical trials, such as PARADIGM-HF, demonstrated that combining a neprilysin inhibitor (Sacubitril) with valsartan was superior to the standard guideline-directed therapy with a RAAS inhibitor alone (enalapril) [33].”
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,388
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132 · cited 1×
“They produce neuro-hormonal modulation via the activation of the renin–angiotensin–aldosterone system (RAAS) in response to hypoperfusion, leading to sodium retention, vasoconstriction, and intravascular volume depletion [5].”
BackgroundHeart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Borlaug, B. A., & Paulus, W. J. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq426 · Cited by 1,093
Cited by
Renal nerves in physiology, pathophysiology and interoception
Evans, L. C., Dayton, A., & Osborn, J. W. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00893-3 · Cited by 46
Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis
Salajová, K. B., Malík, J., & Valeriánová, A. (2024) · Physiological Research · doi:10.33549/physiolres.935110 · Cited by 29
The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF
Triposkiadis, F. K., Briasoulis, Α., Sarafidis, P. A., Magouliotis, D. E., Athanasiou, T., PARASKEVAIDIS, I. A., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206486 · Cited by 20
Goyal, A., Jain, H., Verma, A., Jain, J., Shamim, U., Kanagala, S. G., Motwani, J., Dey, R. C., Chunawala, Z. S., Sohail, A. H., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102196 · Cited by 17
Shen, Z., Zhang, Y., Bu, G., & Fang, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112778 · Cited by 17
Metadata
- Authors
- Kassab, K., Soni, R., Kassier, A., & Fischell, T. A.
- Affiliations
- Borgess Medical Center (US)
- Corresponding author
- Kassab, Kameel
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-07-17
- Volume
- 11
- Issue
- 14
- Pages
- 4147
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9324976
- OpenAlex
- W4285731655
- Cited by
- 19
- References
- 60
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 3
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- renal denervation, heart failure, sympathetic activation, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, neurohormonal activation, hypertension, sympathetic outflow, heart failure prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Potential Role of Renal Denervation in the Management of Heart Failure. https://app.cochat.ai/papers/10.3390/jcm11144147
- The paper
- Kassab, K., Soni, R., Kassier, A., & Fischell, T. A. (2022). The Potential Role of Renal Denervation in the Management of Heart Failure. Journal of Clinical Medicine. https://doi.org/10.3390/jcm11144147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
